Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,305 papers from all fields of science
Search
Sign In
Create Free Account
NVP BEZ235
Known as:
NVP-BEZ235
, NVPBEZ235
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
dactolisib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
Liang-qing Li
,
Shengwei Zhang
,
Diya Xie
,
Hui Chen
,
Xuelan Zheng
,
D. Pan
OncoTargets and Therapy
2018
Corpus ID: 52898885
Purpose NVP-BEZ235 is a recently developed dual inhibitor of PI3K and mTOR and shows good inhibitory effects on several types of…
Expand
2015
2015
Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma
P. Anders
,
P. Bhende
,
M. Foote
,
D. Dittmer
,
Steven I. Park
,
B. Damania
Leukemia and Lymphoma
2015
Corpus ID: 23545315
NHL subtypes are classified based on clinical and histologic characteristics, as well as lymphocyte developmental stage. NHL sub…
Expand
2015
2015
Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor…
S. Schrauwen
,
Jeroen Depreeuw
,
Lieve Coenegrachts
,
Els Hermans
,
D. Lambrechts
,
F. Amant
Gynecologic Oncology
2015
Corpus ID: 205799552
2014
2014
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell Lines
L. Maute
,
Johannes Wicht
,
L. Bergmann
2014
Corpus ID: 56803798
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumors still associated with poor…
Expand
2013
2013
Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down‐regulation of Mcl‐1 in mantle cell lymphoma
A. Müller
,
C. Zang
,
Cindrilla Chumduri
,
B. Dörken
,
P. Daniel
,
C. Scholz
International Journal of Cancer
2013
Corpus ID: 24439126
Mantle cell lymphoma (MCL) is an aggressive form of Non‐Hodgkin‐lymphoma (NHL) with an ongoing need for novel treatments. Apart…
Expand
2012
2012
RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
B. Nyfeler
,
Yan Chen
,
+11 authors
A. Huang
PLoS ONE
2012
Corpus ID: 6712616
The mammalian target of rapamycin (mTOR) is regulated by oncogenic growth factor signals and plays a pivotal role in controlling…
Expand
2012
2012
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy
M. Civallero
,
M. Cosenza
,
L. Marcheselli
,
S. Pozzi
,
S. Sacchi
Expert Opinion on Investigational Drugs
2012
Corpus ID: 3088482
Objectives: Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma; the complete response rate for standard…
Expand
2012
2012
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
A. Kim
,
Sunhoo Park
,
+4 authors
Seung-Sook Lee
Leukemia research : a Forum for Studies on…
2012
Corpus ID: 206722388
2010
2010
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
P. Nanni
,
G. Nicoletti
,
+12 authors
P. Lollini
European Journal of Cancer
2010
Corpus ID: 5080920
Highly Cited
2009
Highly Cited
2009
Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Dexin Kong
,
S. Yaguchi
,
T. Yamori
Biological and Pharmaceutical Bulletin
2009
Corpus ID: 29449925
Phosphatidylinositol 3-kinase (PI3K) has been implicated in a variety of diseases including cancer. A number of PI3K inhibitors…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE